Phase 2 UNITY-NHL Study Regarding Umbralisib
Apr 15, 2021 ·
2m 31s
Owen A. O’Connor, Chief Scientific Officer at TG Therapeutics, describes the phase 2 UNITY-NHL study, the results of which led to the FDA’s approval of umbralisib.
Information
| Author | Peter Ciszewski, CheckRare |
| Website | - |
| Tags |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
